This proposal presents the coherent clinical oncology activities at the University of California, San Francisco and its participation in the Northern California Oncology Group (NCOG). Over the past 5 years we have demonstrated an ability to perform coordinated, multidisciplinary research independently and in this cooperative group. Recognizing the modest level of funding previously provided, we have provided data of excellent quality and quantity. Particularly noteworthy have been the following: 1. We have provided the largest single institutional patient input to all clinical NCOG studies - 774/3157 (24%) from 6/77 to 6/82 and 175/624 (28%) in 1982, and expect to provide 275-300 patients/year by 1983. 2. We have demonstrated a major scientific ability in proposing roughly 50% of new NCOG studies (including Phase I, II, III studies). 3. We have generated multidisciplinary cooperative activities with 2 or 3 modalities in 10 NCOG studies. 4. We have utilized our expertise in Clinical Pharmacology and Pharmacokinetics (Misonidazole + L-PAM, Elliptinium and BUDR studies). 5. We have had a major leadership role in the NCOG with participation on all committees (leadership of the Medical Oncology, Surgery, and Radiation Therapy Committees as well as 14 other committees). 6. We have designed, developed, and streamlined the data management and statistical information records, designed protocol manuals, provided training facilities, and offered scientific and logistical criticism of protocols. 7. We have had more group-related scientific publications (1981-82) than any other NCOG member (more than 12 abstracts and 11 articles). We have been a major resource for patients and science in the areas of combined modality trials and protocols for gastrointestinal, breast and central nervous system malignancies. We expect over the next several years to enhance and improve these activities. UCSF is a unique resource of demonstrated ability for the NCOG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA025827-05S1
Application #
3556765
Study Section
Cancer Regional Studies Review Committee (CRS)
Project Start
1979-08-01
Project End
1988-01-31
Budget Start
1986-02-10
Budget End
1988-01-31
Support Year
5
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Sneed, P K; Stauffer, P R; McDermott, M W et al. (1998) Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 40:287-95
Sneed, P K; Lamborn, K R; Larson, D A et al. (1996) Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 35:37-44
Sneed, P K; Prados, M D; McDermott, M W et al. (1995) Large effect of age on the survival of patients with glioblastoma treated with radiotherapy and brachytherapy boost. Neurosurgery 36:898-903;discussion 903-4
Sneed, P K; Gutin, P H; Larson, D A et al. (1994) Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 29:719-27
Gutin, P H; Prados, M D; Phillips, T L et al. (1991) External irradiation followed by an interstitial high activity iodine-125 implant ""boost"" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. Int J Radiat Oncol Biol Phys 21:601-6
Carlson, R W; Sikic, B I; Gandara, D R et al. (1991) Late consolidative radiation therapy in the treatment of limited-stage small cell lung cancer. Cancer 68:948-58
Phillips, T L; Levin, V A; Ahn, D K et al. (1991) Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study. Int J Radiat Oncol Biol Phys 21:709-14
Gandara, D R; Valone, F H; Perez, E A et al. (1991) Rapidly alternating radiotherapy and high dose cisplatin chemotherapy in stage IIIB non-small cell lung cancer: results of a phase I/II study. Int J Radiat Oncol Biol Phys 20:1047-52
Gandara, D R; Perez, E A; Wold, H et al. (1990) High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group. Cancer Chemother Pharmacol 27:243-7
Valone, F H; Friedman, M A; Wittlinger, P S et al. (1989) Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol 7:1427-36

Showing the most recent 10 out of 21 publications